ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Official Title

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)

Summary:

A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.

Trial Description

Primary Outcome:

• Registration of 80 patients within twenty four months

Secondary Outcome:

• CRFS
• GRFS
• Survival
• Complete data collection
• Cost of study

Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.

View this trial on ClinicalTrials.gov